Thrive Wealth Management LLC Reduces Position in Danaher Co. (NYSE:DHR)

Thrive Wealth Management LLC trimmed its position in Danaher Co. (NYSE:DHR) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,765 shares of the conglomerate’s stock after selling 353 shares during the quarter. Thrive Wealth Management LLC’s holdings in Danaher were worth $1,323,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Trueblood Wealth Management LLC grew its position in shares of Danaher by 4.4% in the 4th quarter. Trueblood Wealth Management LLC now owns 3,532 shares of the conglomerate’s stock worth $811,000 after buying an additional 150 shares during the last quarter. Mechanics Bank Trust Department boosted its holdings in Danaher by 14.8% in the fourth quarter. Mechanics Bank Trust Department now owns 9,233 shares of the conglomerate’s stock valued at $2,119,000 after acquiring an additional 1,193 shares in the last quarter. Diversify Wealth Management LLC increased its position in Danaher by 7.8% during the 4th quarter. Diversify Wealth Management LLC now owns 8,186 shares of the conglomerate’s stock valued at $1,924,000 after purchasing an additional 592 shares during the period. Hall Laurie J Trustee raised its holdings in Danaher by 5.2% in the 4th quarter. Hall Laurie J Trustee now owns 21,669 shares of the conglomerate’s stock worth $4,974,000 after purchasing an additional 1,065 shares in the last quarter. Finally, Ballast Inc. lifted its position in shares of Danaher by 4.9% in the 4th quarter. Ballast Inc. now owns 5,250 shares of the conglomerate’s stock worth $1,205,000 after purchasing an additional 245 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $238.41 on Monday. The firm has a market cap of $172.20 billion, a P/E ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $234.85 and a 200 day moving average of $253.42.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DHR shares. UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Finally, Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.